Ottimo Pharma
Ottimo Pharma is a clinical-stage biotechnology company developing a first-in-class PD-1/VEGFR2 dual-paratopic antibody (Jankistomig/OTP-01) for solid tumor cancers, currently in Phase I/IIA clinical trials across the US and Australia.
- Company typePrivate
- Founded2020
- HeadquartersSandwich, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ottimo Pharma does
Ottimo Pharma is a clinical-stage biotechnology company developing first-in-class PD-1/VEGFR2 dual-paratopic antibodies for the treatment of solid tumor cancers. The company's lead and effectively sole clinical asset is Jankistomig (also designated OTP-01), an Fc-null IgG1 monoclonal antibody featuring a proprietary dual-paratopic (biparatopic) architecture that simultaneously engages the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway within the tumor microenvironment. The molecule is designed for tumor microenvironment-biased distribution, allosteric VEGFR2 inhibition targeting ligands A/C/D, reduced systemic Avastin-like toxicity, and conventional IgG manufacturability and stability, positioning it as a potential combination backbone with ADCs or chemotherapy. The asset is investigational; Ottimo is pre-revenue and does not currently sell any product.
The company is UK-registered (Ottimo Pharma Limited, company number 10650475) with its registered office in Sandwich, Kent and operational presence in Boston, Massachusetts. It was co-founded in 2020 by Medicxi and scientific founder Jonny Finlay, operated in stealth for approximately three years, and emerged publicly in October 2024 under Chair & CEO David Epstein (former CEO of Seagen and Novartis Pharmaceuticals). The $140M+ Series A closed in December 2024 funded a Phase I/IIA adaptive trial; FDA IND clearance was secured in January 2026, the first patient was dosed, and the study is running across leading oncology centers in the US and Australia with planned expansion to approximately 20 centers globally. All clinical manufacturing of OTP-01 is conducted in the US via an expanded partnership with Lotte Biologics at its Syracuse Bio Campus.
The business model is a standard clinical-stage biotech construct: future revenue is expected from product sales upon regulatory approval or, alternatively, from strategic partnership/licensing transactions with major pharmaceutical companies covering co-development and commercialization rights, with no current pricing model in place. The target customer is ultimately oncology patients with solid tumors, particularly those who may benefit from combined PD-1 and anti-angiogenic therapy; in the near term, the company serves clinical trial investigators and sites. Manufacturing is single-source through Lotte Biologics, creating a known supply-chain concentration that will need to be de-risked as the asset advances.
Ottimo Pharma firmographics
Firmographics- Name
- Ottimo Pharma
- Legal name
- Ottimo Pharma Limited
- Website
- https://ottimopharma.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ottimo Pharma is a clinical-stage biotechnology company developing a first-in-class PD-1/VEGFR2 dual-paratopic antibody (Jankistomig/OTP-01) for solid tumor cancers, currently in Phase I/IIA clinical trials across the US and Australia.
- Ownership category
- akta.pro rank
Where Ottimo Pharma is headquartered
LocationHeadquarters
- HQ city
- Sandwich
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Ottimo Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotech company developing novel antibody therapeutics for cancer. Expected to generate revenue through product sales following regulatory approval or through strategic partnerships/licensing deals with major pharmaceutical companies for co-development and commercialization rights.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Ottimo Pharma product offering
Product offeringCore offering
Ottimo Pharma is a clinical-stage biotech company developing OTP-01 (Jankistomig), a first-in-class Fc-null IgG1 monoclonal antibody featuring a dual-paratopic design that simultaneously engages the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway for the treatment of solid tumors. The company is advancing the candidate through Phase I/IIA clinical trials and plans eventual commercialization through partnership with major pharmaceutical companies or independent launch.
Product overview
Ottimo Pharma is a clinical-stage biotech company developing a single lead product, Jankistomig (also referred to as OTP-01), a first-in-class PD-1/VEGFR2 dual-paratopic antibody for multiple solid tumor indications. The product is designed as a single-agent IgG1 therapy combining immune checkpoint inhibition with angiogenesis targeting in one molecule, offering a differentiated approach from traditional bispecific antibody fusions.
Differentiator
Problem solved
Functional benefit
Products and services
- OTP-01 (Jankistomig) A first-in-class, investigational Fc-null, IgG1 monoclonal antibody featuring a unique dual-paratopic design enabling simultaneous engagement of the PD-1 immune checkpoint and VEGFR-2 angiogenic pathway. Designed as a single-agent therapy for solid tumors that delivers cooperative binding of immune checkpoint inhibition and angiogenesis in the tumor microenvironment.
Quantifiable outcome
- Significantly improved anti-tumor efficacy compared to PD-1 inhibition alone in preclinical studies
- +2 more outcomes
Companies that use Ottimo Pharma
Customer profileSegments1 record
Ideal customer profiles2 records
Ottimo Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ottimo Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Lotte BiologicscoreExpanded partnership with UK-based Lotte Biologics for antibody drug manufacturing and process development. Lotte Biologics will produce the active pharmaceutical ingredient (DS) for Ottimo's biparatopic antibody candidate Jankistomig (OTP-01) at its Syracuse Bio Campus in New York. The deal extends beyond simple manufacturing to include process development, marking deeper integration into Ottimo's drug development pipeline with potential for long-term commercialization cooperation. The partnership reflects Ottimo's confidence in Lotte Biologics' manufacturing capabilities and quality standards.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Ottimo Pharma competitors and assessment
Company assessmentDirect peers
- Akeso: China-based biotech that developed ivonescimab, a PD-1/VEGF bispecific antibody approved in China and with positive Phase III data in NSCLC. Akeso is the most direct competitor to Ottimo's PD-1/VEGFR2 dual mechanism, and its clinical/commercial progress directly benchmarks OTP-01's potential.
- Compugen: Clinical-stage immuno-oncology company using a computational biology platform to discover novel drug targets and develop antibody therapeutics. Comparable to Ottimo as a platform-driven oncology antibody developer focused on novel immune mechanisms.
- CytomX Therapeutics: Clinical-stage oncology company developing Probody therapeutics — masked antibodies designed to be activated in the tumor microenvironment. Comparable to Ottimo as a clinical-stage antibody platform company engineering tumor-microenvironment-biased activity.
- Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune agonists. Comparable as a clinical-stage antibody-platform company focused on novel immuno-oncology mechanisms.
- Werewolf Therapeutics: Clinical-stage oncology company developing conditionally activated INDUKINE therapeutics designed to be activated in the tumor microenvironment. Comparable to Ottimo as a clinical-stage developer of engineered antibody-based cancer therapies with novel selectivity mechanisms.
- MacroGenics: Clinical-stage biotech developing bispecific antibodies and antibody-based therapeutics for cancer, including PD-1- and VEGF-related programs. Comparable to Ottimo as a developer of multi-specific antibody oncology therapeutics.
- Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Comparable to Ottimo as a clinical-stage antibody-platform company building combination-ready oncology therapeutics.
- Cullinan Oncology: Clinical-stage oncology company developing a diversified pipeline of immuno-oncology and targeted therapeutics. Comparable to Ottimo as a clinical-stage biotech with a lead oncology asset advancing through early-phase trials with similar development-stage risk profile.
- Mersana Therapeutics: Clinical-stage oncology company developing novel antibody-drug conjugates using its Dolasynthen and Immunosynthen platforms. Comparable to Ottimo as a clinical-stage antibody-platform company developing next-generation cancer therapeutics with platform extensibility.
Emerging players
- Janux Therapeutics: Clinical-stage biotech developing T cell engager (TCE) immunotherapies for cancer using a tumor-activated technology platform. Comparable to Ottimo as an early-stage oncology antibody company engineering safer, more selective cancer immunotherapies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Ottimo Pharma social profiles
Digital presenceOttimo Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ottimo Pharma leadership team
Management profileNumber of profiles
Profiles14 records
Ottimo Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ottimo Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ottimo Pharma
What does Ottimo Pharma do?
Ottimo Pharma is a clinical-stage biotech company developing OTP-01 (Jankistomig), a first-in-class Fc-null IgG1 monoclonal antibody featuring a dual-paratopic design that simultaneously engages the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway for the treatment of solid tumors. The company is advancing the candidate through Phase I/IIA clinical trials and plans eventual commercialization through partnership with major pharmaceutical companies or independent launch.
Is Ottimo Pharma a public or private company?
Ottimo Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ottimo Pharma founded?
Ottimo Pharma was founded in 2020. It employs 1 to 10 people.
Where is Ottimo Pharma based?
Ottimo Pharma is headquartered in Sandwich, United Kingdom, in the Europe region.
How does Ottimo Pharma make money?
One revenue line is on record: pharmaceutical Development and Commercialization.
Who are Ottimo Pharma's main competitors?
Direct peers on record are Akeso, Compugen, CytomX Therapeutics, Bolt Biotherapeutics, Werewolf Therapeutics, MacroGenics, Pyxis Oncology, Cullinan Oncology and Mersana Therapeutics. Janux Therapeutics is listed as an emerging player.
Does Ottimo Pharma have an API?
No public API is recorded for Ottimo Pharma.